Latest Breaking News On - China cardiovascular health - Page 1 : vimarsana.com

Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

United statesHong kongYong huoEli lillyEquecabtagene autoleucelYujie zhouInnovent biologicsAdimab incyteIncyte corporationUniversity first hospitalAnzhen hospital affiliated to capital medical universityMd anderson cancer centerZhongshan hospital affiliated to fudan universityChina national medical products administrationChina cardiovascular healthClinical development of innovent

Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

/PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

United statesHong kongInnovent biologicsAdimab incyteYong huoEli lillyAmerican cardiology association annual congressAmerican heart associationPrnewswire innovent biologics incChina cardiovascular healthMd anderson cancer centerChina national medical products administrationUniversity first hospitalIncyte corporationScientific sessionsNational medical products administration

Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongInnovent biologicsAdimab incyteYong huoEli lillyAmerican cardiology association annual congressAmerican heart associationPrnewswire innovent biologics incChina cardiovascular healthMd anderson cancer centerChina national medical products administrationCompany codesUniversity first hospitalIncyte corporationScientific sessions

Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

United statesHong kongInnovent biologicsAdimab incyteYujie zhouYong huoEli lillyClinical development of innoventPrnewswire innovent biologics incChina cardiovascular healthCapital medical universityMd anderson cancer centerNational scienceChina national medical products administrationUniversity first hospitalInnovent or company

Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022

Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022 - read this article along with other careers information, tips and advice on BioSpace

United statesHong kongInnovent biologicsAdimab incyteYujie zhouEli lillyAmerican cardiology association annual congressPrnewswire innovent biologics incChina cardiovascular healthCapital medical universityMd anderson cancer centerAmerican college of cardiology annual congressCompany codesIncyte corporationAmerican collegeCardiology annual congress